Delta Hat, Bramley House, Nottingham, NG10 3SX, UK.
University of Southampton, University Road, Southampton, SO17 1BJ, UK.
Future Oncol. 2024 Mar;20(8):459-470. doi: 10.2217/fon-2023-0372. Epub 2023 Aug 2.
The cost-effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed. A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost-effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY). Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses. Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.
在苏格兰，评估了avelumab 一线维持治疗局部晚期或转移性尿路上皮癌的成本效益。通过比较avelumab 联合最佳支持治疗（BSC）与单独 BSC，开发了一个分割生存模型，该模型纳入了 JAVELIN Bladder 100 试验数据、国家数据库和已发表文献中的成本，以及临床专家对假设的验证。使用终生成本和质量调整生命年（QALY）估计增量成本效益比（ICER）。avelumab 联合 BSC 的增量成本为 9446 英镑，QALY 增加了 0.63，导致基于案例的（确定性）ICER 为每获得一个 QALY 增加 15046 英镑，稳健的敏感性分析支持这一结果。avelumab 一线维持治疗可能是苏格兰局部晚期或转移性尿路上皮癌的一种具有成本效益的治疗方法。
